LumiraDx, Health Care SPAC Slash $2B From Deal Value
Diagnostic testing company LumiraDx and a special purpose acquisition company said Friday they cut the value of their merger by 40%, saying a rocky climate for COVID-19 testing led them to...To view the full article, register now.
Already a subscriber? Click here to view full article